Fig. 3From: Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritisProportion of patients achieving clinically meaningful improvement in FACIT-Fatigue score (≥4-point increase [21]) through week 52 in a DISCOVER-1 and b DISCOVER-2Back to article page